All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
More information on our cookie policy.
BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Artificial intelligence
Coronavirus
Diagnosing and tracking COVID-19
Drugs to Watch 2020
The next pandemic
Premium reports
BioWorld Financings Reports
Disease Forecast Reports
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, April 11, 2021
Home
» Phase III study of mRNA-1273 for COVID-19 meets primary efficacy endpoint at interim analysis
Phase III study of mRNA-1273 for COVID-19 meets primary efficacy endpoint at interim analysis
Nov. 16, 2020
No Comments
Article reprints
Source:
https://science.bioworld.com/ddn/article.do?id=174922
BioWorld Science
Related Articles
U.S. phase III trial of AZD-1222 for COVID-19 meets primary efficacy endpoint at interim analysis
